Figure 1.
Loss of Morrbid enhances the survival of Shp2E76K-driven JMML mice. (A) Generation of JMML mice (Shp2*: LysMCre; Shp2E76K/+) and JMML mice lacking Morrbid (Shp2*M: LysMCre; Shp2E76K/+; Morrbid−/−) along with WT control and Morrbid−/− (M). (B) Kaplan-Meier survival curve of Shp2* and Shp2*M mice and control animals. (C) Analysis of hematopoietic cells in PB by the automatic blood cell counter Element HT5 Analyzer. (D) Analysis of WBCs from PB by flow cytometry. Mac1+ staining for myeloid cells and CD19+ staining for B cells (n = 4-18 mice). *P < .05; **P < .01; ***P < .001; ****P < .0001. See supplemental Figure 1 for improvement of the anemia phenotype in Shp2*M mice compared with Shp2* mice. LY, lymphocytes; n.s., not significant.

Loss of Morrbid enhances the survival of Shp2E76K-driven JMML mice. (A) Generation of JMML mice (Shp2*: LysMCre; Shp2E76K/+) and JMML mice lacking Morrbid (Shp2*M: LysMCre; Shp2E76K/+; Morrbid−/−) along with WT control and Morrbid−/− (M). (B) Kaplan-Meier survival curve of Shp2* and Shp2*M mice and control animals. (C) Analysis of hematopoietic cells in PB by the automatic blood cell counter Element HT5 Analyzer. (D) Analysis of WBCs from PB by flow cytometry. Mac1+ staining for myeloid cells and CD19+ staining for B cells (n = 4-18 mice). *P < .05; **P < .01; ***P < .001; ****P < .0001. See supplemental Figure 1 for improvement of the anemia phenotype in Shp2*M mice compared with Shp2* mice. LY, lymphocytes; n.s., not significant.

Close Modal

or Create an Account

Close Modal
Close Modal